CCR6 has a non‐redundant role in the development of inflammatory bowel disease

Antigen‐loaded tissues such as the intestinal mucosa must simultaneously elicit appropriate immune response to innocuous bacteria and food proteins, and to potentially harmful antigens. Impairment of the mechanisms controlling this response may mediate the excessive immune reaction that can lead to tissue destruction and inflammatory intestinal diseases, including inflammatory bowel disease. The intestinal epithelium influences local immune responses through the expression of adhesion molecules, costimulatory factors, cytokines and chemokines. CCL20, a β‐chemokine expressed in epithelia from colon and other intestinal tissue, plays a role in immune responses of intestinal mucosa, as deduced from the defects in intestinal leukocyte homeostasis shown by mice lacking CCR6, the CCL20 receptor. We studied the response of CCR6‐deficient mice in two models of inflammatory bowel disease. The data show that absence of CCR6 resulted in less severe intestinal pathology in animals treated with dextran sodium sulfate. Conversely, CCR6 deficiency alters leukocyte homeostasis and the cytokine environment in the intestinal mucosa; these changes are sufficient to confer susceptibility to trinitrobenzene sulfonic acid‐induced intestinal inflammation in the otherwise resistant C57BL/6J mouse strain. These results suggest that the CCR6/CCL20 axis has a critical, non‐redundant role in the in vivo control of immune responses in the intestine.

[1]  G. Bouma,et al.  Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. , 2002, Gastroenterology.

[2]  R. Blumberg,et al.  The immunology of mucosal models of inflammation. , 2002, Annual review of immunology.

[3]  C. Nagler‐Anderson Man the barrier! strategic defences in the intestinal mucosa , 2001, Nature reviews. Immunology.

[4]  M. Leach,et al.  Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL‐10– / – mice and Rag‐2– / – mice reconstituted with CD4+CD45RBhigh T cells , 2001, European journal of immunology.

[5]  J. Cyster,et al.  Chemokines in lymphopoiesis and lymphoid organ development. , 2001, Current opinion in immunology.

[6]  M. Kagnoff,et al.  Regulated MIP-3alpha/CCL20 production by human intestinal epithelium: mechanism for modulating mucosal immunity. , 2001, American journal of physiology. Gastrointestinal and liver physiology.

[7]  C. Martínez-A,et al.  CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. , 2001, The Journal of clinical investigation.

[8]  B. Rollins,et al.  Chemokines and disease , 2001, Nature Immunology.

[9]  Bernhard Moser,et al.  Lymphocyte traffic control by chemokines , 2001, Nature Immunology.

[10]  C. Caux,et al.  Macrophage Inflammatory Protein 3α Is Expressed at Inflamed Epithelial Surfaces and Is the Most Potent Chemokine Known in Attracting Langerhans Cell Precursors , 2000, The Journal of experimental medicine.

[11]  J. Mcghee,et al.  Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. , 2000, Gastroenterology.

[12]  C. Caux,et al.  Up-Regulation of Macrophage Inflammatory Protein-3α/CCL20 and CC Chemokine Receptor 6 in Psoriasis1 , 2000, The Journal of Immunology.

[13]  Atsushi Mizoguchi,et al.  Mice with a Selective Deletion of the CC Chemokine Receptors 5 or 2 Are Protected from Dextran Sodium Sulfate-Mediated Colitis: Lack of CC Chemokine Receptor 5 Expression Results in a NK1.1+ Lymphocyte-Associated Th2-Type Immune Response in the Intestine1 , 2000, The Journal of Immunology.

[14]  H. Greenberg,et al.  CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. , 2000, Immunity.

[15]  A. Iwasaki,et al.  Localization of Distinct Peyer's Patch Dendritic Cell Subsets and Their Recruitment by Chemokines Macrophage Inflammatory Protein (Mip)-3α, Mip-3β, and Secondary Lymphoid Organ Chemokine , 2000, The Journal of experimental medicine.

[16]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[17]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[18]  C. Mackay,et al.  The role of chemokine receptors in primary, effector, and memory immune responses. , 2000, Annual review of immunology.

[19]  R. Blumberg,et al.  First line of defense: the role of the intestinal epithelium as an active component of the mucosal immune system , 2000, Journal of Gastroenterology.

[20]  E. Kriehuber,et al.  Macrophage Inflammatory Protein 3α Is Involved in the Constitutive Trafficking of Epidermal Langerhans Cells , 1999, The Journal of experimental medicine.

[21]  R. Blumberg,et al.  Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. , 1999, Current opinion in immunology.

[22]  C. Martínez-A,et al.  Down‐regulation of the β‐chemokine receptor CCR6 in dendritic cells mediated by TNF‐α and IL‐4 , 1999, Journal of leukocyte biology.

[23]  R. N. Smith,et al.  Colitis in transgenic and knockout animals as models of human inflammatory bowel disease , 1999, Immunological reviews.

[24]  M. Manns,et al.  Enhanced production of monocyte chemotactic protein 3 in inflammatory bowel disease mucosa , 1999, Gut.

[25]  Y. Tanaka,et al.  Selective expression of liver and activation‐regulated chemokine (LARC) in intestinal epithelium in mice and humans , 1999, European journal of immunology.

[26]  R. Rabin,et al.  CC-Chemokine Receptor 6 Is Expressed on Diverse Memory Subsets of T Cells and Determines Responsiveness to Macrophage Inflammatory Protein 3α , 1999, The Journal of Immunology.

[27]  E. Bloemena,et al.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines , 1998, Clinical and experimental immunology.

[28]  Á. Zaballos,et al.  Molecular cloning, functional characterization and mRNA expression analysis of the murine chemokine receptor CCR6 and its specific ligand MIP‐3α 1 , 1998 .

[29]  C. Caux,et al.  Selective Recruitment of Immature and Mature Dendritic Cells by Distinct Chemokines Expressed in Different Anatomic Sites , 1998, The Journal of experimental medicine.

[30]  B. Ludviksson,et al.  The Pathogenesis of Mucosal Inflammation in Murine Models of Inflammatory Bowel Disease and Crohn Disease , 1998, Annals of Internal Medicine.

[31]  A. Lentsch,et al.  In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. , 1997, The Journal of clinical investigation.

[32]  T. Mcclanahan,et al.  CCR6, a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3α and Is Highly Expressed in Human Dendritic Cells , 1997, The Journal of experimental medicine.

[33]  A. Mantovani,et al.  Cloning and Characterization of a Specific Receptor for the Novel CC Chemokine MIP-3α from Lung Dendritic Cells , 1997, The Journal of experimental medicine.

[34]  S. Ullrich,et al.  STRL22 is a receptor for the CC chemokine MIP-3alpha. , 1997, Biochemical and biophysical research communications.

[35]  C. Kelly,et al.  Enterocytes are the primary source of the chemokine ENA-78 in normal colon and ulcerative colitis. , 1997, The American journal of physiology.

[36]  H. Nomiyama,et al.  Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC* , 1997, The Journal of Biological Chemistry.

[37]  M. Klemsz,et al.  Cloning and Characterization of Exodus, a Novel β-Chemokine , 1997 .

[38]  T. Mcclanahan,et al.  Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3alpha and MIP-3beta. , 1997, Journal of immunology.

[39]  T. Mcclanahan,et al.  CCR 6 , a CC Chemokine Receptor that Interacts with Macrophage Inflammatory Protein 3 a and Is Highly Expressed in Human Dendritic Cells , 1997 .

[40]  A. Lentsch,et al.  In Vivo Suppression of NFk B and Preservation of I k B a by Interleukin-10 and Interleukin-13 , 1997 .

[41]  M. Fishman,et al.  Impaired Defense of Intestinal Mucosa in Mice Lacking Intestinal Trefoil Factor , 1996, Science.

[42]  J. Mcghee,et al.  Hapten-induced model of murine inflammatory bowel disease: mucosa immune responses and protection by tolerance. , 1996, Journal of immunology.

[43]  M. Leach,et al.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. , 1996, The Journal of clinical investigation.

[44]  P. Pavli,et al.  Enhanced expression and production of monocyte chemoattractant protein‐1 in inflammatory bowel disease mucosa , 1996, Journal of leukocyte biology.

[45]  L. Mazzucchelli,et al.  DIFFERENTIAL IN SITU EXPRESSION OF THE GENES ENCODING THE CHEMOKINES MCP‐1 AND RANTES IN HUMAN INFLAMMATORY BOWEL DISEASE , 1996, The Journal of pathology.

[46]  L. Mazzucchelli,et al.  DIFFERENTIAL IN SITU EXPRESSION OF THE RANTES IN HUMAN INFLAMMATORY BOWEL DISEASE GENES ENCODING THE CHEMOKINES MCP-1 AND , 1996 .

[47]  M. Neurath,et al.  Antibodies to interleukin 12 abrogate established experimental colitis in mice , 1995, The Journal of experimental medicine.

[48]  L. Mazzucchelli,et al.  Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. , 1994, The American journal of pathology.

[49]  Russell Higuchi,et al.  Kinetic PCR Analysis: Real-time Monitoring of DNA Amplification Reactions , 1993, Bio/Technology.

[50]  T. Ohkusa,et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. , 1990, Gastroenterology.